WebDoctor Encyclopedia

Liver, bile ducts & pancreas

Mucinous cystic neoplasm of the pancreas

A mucinous cystic neoplasm is a mucus-filled cyst in the tail of the pancreas, found almost only in women. Most are benign, but some contain cancer, so surgery is usually advised, while small cysts without nodules may be watched.

Medically reviewed Last reviewed October 20, 2026

What is a mucinous cystic neoplasm of the pancreas?

A mucinous cystic neoplasm (MCN) is a fluid-filled growth in the pancreas that is lined by cells producing mucin, a thick, slimy substance. Its defining feature is a layer of tissue under the lining that looks like the stroma of the ovary. This ovarian-type stroma separates MCNs from other cystic growths of the pancreas, such as intraductal papillary mucinous neoplasms (IPMNs), with which they were once confused (Crippa et al., 2008).

The pancreas is a gland lying behind the stomach. It makes digestive juices and hormones such as insulin. MCNs almost always occur in the body or tail of the pancreas, the part that extends towards the spleen, and they do not connect with the main pancreatic duct.

MCNs are found almost exclusively in women, usually in middle age. Many cause no symptoms and are discovered by chance on a scan done for another reason. Most are benign, but they are considered precancerous: a minority contain high-grade changes or an invasive cancer, and the risk rises with size and with solid lumps (nodules) in the cyst wall (Pollini et al., 2023).

Treatment is usually surgery to remove the part of the pancreas containing the cyst. Recent research suggests that some small, simple MCNs could safely be watched with scans instead. When the cyst is removed before cancer develops, the outlook is excellent.

1. Key facts at a glance

Feature Details
What it is A mucin-producing cyst of the pancreas with ovarian-type stroma
Who is affected Women in about 95% of cases; average age in the 40s
Location Body or tail of the pancreas in almost all cases
Connection to the main duct None
Symptoms Often none; mild abdominal pain is the most common
Risk of cancer About 16% of removed MCNs are malignant in pooled data
Warning features Size 4 cm or more, wall nodules
Main treatment Distal pancreatectomy, often by keyhole surgery
Outlook Excellent without invasive cancer; more guarded with it

2. Types

MCNs are graded by how abnormal the lining cells look under the microscope.

Grade Description Behaviour
Low-grade dysplasia Lining cells only mildly abnormal Benign; cured by removal
High-grade dysplasia Severely abnormal cells, but no invasion Precancer; cured by removal
MCN with associated invasive carcinoma Cancer cells have grown through the wall Behaves like pancreatic cancer, though often better

In a series of 163 operated patients, 72% had a benign adenoma, about 10% a borderline tumour, about 5% carcinoma in situ and 12% an invasive cancer (Crippa et al., 2008). Older terms such as adenoma and borderline tumour have been replaced by the low-grade and high-grade categories.

How MCNs differ from other pancreatic cysts

Cyst type Typical patient Location Duct connection Cancer risk
Mucinous cystic neoplasm Middle-aged woman Body or tail No Moderate
Intraductal papillary mucinous neoplasm (IPMN) Older man or woman Anywhere, often head Yes Low to high, depending on type
Serous cystadenoma Older woman Anywhere No Very low
Solid pseudopapillary neoplasm Young woman Anywhere No Low-grade malignancy
Pseudocyst After pancreatitis Anywhere Sometimes None

3. Causes and risk factors

Factor Notes
Female sex The strongest association; MCNs are very rare in men
Middle age Average age around 45-50
Hormones The ovarian-type stroma carries hormone receptors, suggesting a hormonal link
Embryonic development One theory is that ovarian tissue lodges near the pancreas during early development

The exact cause is unknown. There is no clear link with smoking, alcohol or diet, and MCNs are not usually inherited. Patients with invasive cancer tend to be older than those with benign cysts, which supports the idea that the lining gradually progresses from benign to malignant (Crippa et al., 2008).

4. How does it look

On scans

Feature Typical appearance
Shape Round, smooth-walled cyst
Inside One large space or a few large compartments
Wall Thin, sometimes with eggshell-like calcium on the rim
Duct The main pancreatic duct is usually normal
Worrying signs Thick wall, solid nodules, size above 4-6 cm, a dilated duct

Imaging tests

Test What it adds
CT scan Size, position, wall and calcification
MRI with MRCP Detail of the cyst and its relation to the ducts
Endoscopic ultrasound (EUS) Close-up images of the wall and nodules
EUS-guided fluid sampling Fluid tests for mucin, CEA and cancer cells
PET-CT Sometimes used when cancer is suspected

Preoperative diagnosis relies on combining these tests with the patient’s features (Testini et al., 2010).

Under the microscope

The pathologist confirms the diagnosis by finding mucin-producing lining cells over ovarian-type stroma. The whole cyst is examined, because invasive cancer can be patchy and may be missed if only part is sampled.

5. Symptoms

Common symptoms

  • No symptoms in a sizable share of people; in one large series about 1 in 4 cysts were found by chance (Crippa et al., 2008)
  • Mild, dull pain in the upper abdomen or left side, the most frequent complaint in pooled data (Solis-Pazmino et al., 2024)
  • A feeling of fullness after small meals

Less common symptoms

Symptom Possible cause
Acute pancreatitis Inflammation of the pancreas; affected 9% of patients in one series
A lump felt in the abdomen Very large cyst
Weight loss Large cyst or invasive cancer
Back pain Invasive cancer
New diabetes Rare; damage to the pancreas
Jaundice Very rare, as MCNs are usually in the tail

When to seek medical advice

See a doctor if you have persistent upper abdominal pain, unexplained weight loss or yellowing of the skin. If a pancreatic cyst has been found on a scan, ask to be referred to a pancreas specialist.

6. Diagnosis

Step Purpose
Specialist review of the scan Decides what kind of cyst it is likely to be
Pancreas-protocol CT or MRI Detailed images
Endoscopic ultrasound Looks for nodules and samples fluid if needed
Cyst fluid CEA A raised level suggests a mucinous cyst
Cyst fluid cytology Looks for abnormal cells
Blood CA 19-9 Tumour marker; in pooled data it did not reliably predict cancer
Multidisciplinary team meeting Agrees on surgery or surveillance

A meta-analysis of 1,058 operated patients found that wall nodules were by far the strongest predictor of invasive cancer. Calcification and a raised CA 19-9 were not reliable predictors (Solis-Pazmino et al., 2024).

Features linked with malignancy

Feature Evidence
Mural nodules Strongly linked with malignancy in several studies
Size 4 cm or more No malignant MCN smaller than 4 cm without nodules in the Crippa series
Size around 6 cm or more Associated with malignancy in both Crippa and Pollini data
Older age Invasive cases older on average (55 vs 44 years)

7. Treatment

Guidelines have traditionally advised removing all MCNs (Testini et al., 2010), because of their cancer potential and because most occur in young, fit women. More recent evidence suggests that small MCNs without nodules carry a low risk, and that surveillance may be reasonable in carefully chosen cases (Pollini et al., 2023).

Surgery

Operation When it is used
Laparoscopic or robotic distal pancreatectomy Most MCNs in the body or tail
Spleen-preserving distal pancreatectomy Small, low-risk cysts
Distal pancreatectomy with splenectomy and lymph node removal Suspected or proven cancer
Central pancreatectomy or enucleation Selected small, low-risk cysts
Pancreatoduodenectomy (Whipple) The rare MCN in the head of the pancreas

In the Crippa series, less extensive operations were considered appropriate for low-risk cysts of 4 cm or less without nodules.

Surveillance

Who may be considered How it works
Small cysts without nodules MRI or EUS at regular intervals
Older patients or those with serious illnesses Avoids the risks of surgery
Patients who prefer to avoid surgery after discussion Surgery if the cyst grows or changes

Treatment for invasive cancer

Treatment Notes
Radical surgery Removes the tumour, spleen and nearby lymph nodes
Chemotherapy after surgery Usually offered, as for pancreatic cancer
Chemotherapy for advanced disease Similar to that used for pancreatic ductal adenocarcinoma

Possible complications of surgery

Complication Notes
Pancreatic leak (fistula) The most common problem after distal pancreatectomy
Fluid collection or abscess May need drainage
Bleeding Uncommon
Diabetes Possible, especially if much of the pancreas is removed
Infection risk after splenectomy Vaccinations and sometimes antibiotics are needed

Complications are common but usually manageable; in the Crippa series about half of patients had some complication, but there were no deaths after surgery.

8. Outlook (prognosis)

Situation Outlook
Low-grade or high-grade dysplasia, fully removed Essentially cured; recurrence is not expected
Invasive cancer Five-year disease-specific survival of 57% in one series
Small invasive cancer confined to the cyst Better outlook than larger or spreading cancers

In the Crippa series, recurrence occurred only in patients with invasive cancer. People with non-invasive MCNs had 100% disease-specific survival at five years (Crippa et al., 2008).

Changing estimates of cancer risk

Source Rate of malignancy in removed MCNs
Crippa et al. (2008), 163 patients 17.5%
Pollini et al. (2023), 3,292 patients 16.1% overall; lower in studies published after 2012
Solis-Pazmino et al. (2024), 1,058 patients 13.8% invasive cancer
Earlier literature (Testini et al., 2010) Reported between 6% and 55%

The fall in reported rates probably reflects better diagnosis and the removal of more small, early cysts.

9. Follow-up

Situation Typical follow-up
Non-invasive MCN removed Often no long-term scan surveillance needed
Invasive cancer removed CT and CA 19-9 every 3-6 months for 2 years, then less often
Cyst under surveillance MRI or EUS every 6-12 months at first
After splenectomy Vaccinations and advice on infection
Blood sugar Periodic checks for diabetes

10. Living with a mucinous cystic neoplasm

  • Ask for your scans to be reviewed by a specialist pancreas team
  • Keep surveillance appointments if you are being monitored
  • Report new pain, weight loss or jaundice promptly
  • Have the recommended vaccinations if your spleen is removed
  • Watch for signs of diabetes, such as thirst and passing more urine
  • Take enzyme capsules with meals if you develop greasy stools
  • Eat smaller meals while recovering from surgery
  • Return to exercise gradually, avoiding heavy lifting for several weeks after an open operation

11. Frequently asked questions

Question Answer
Is an MCN cancer? Most are not, but some contain or develop cancer
Do all MCNs need surgery? Surgery is often advised, but small cysts without nodules may be watched
Can men get an MCN? Very rarely
Will I need my spleen removed? Not always; it can sometimes be preserved
Can it come back after removal? Not if it was non-invasive and fully removed
Will I get diabetes? The risk is small after removal of the pancreatic tail
Is it inherited? No
Can I become pregnant afterwards? Yes; pregnancy is generally possible after recovery from surgery
How long is recovery? Most people return to normal activities within 4-8 weeks, sooner after keyhole surgery
Why was a needle test done? Fluid from the cyst helps tell mucinous cysts from harmless ones

12. Questions to ask your care team

  • How certain are you that this is an MCN rather than another type of cyst?
  • Are there nodules or other warning signs?
  • Do you recommend surgery or surveillance, and why?
  • Can the operation be done by keyhole surgery, and can my spleen be saved?
  • What are the risks of the operation?
  • What follow-up will I need afterwards?
  • How many of these operations does your team perform each year?

Resources

  1. Crippa, S. et al. (2008) ‘Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients’, Annals of Surgery, 247(4), pp. 571-579.
  2. Pollini, T. et al. (2023) ‘It is not necessary to resect all mucinous cystic neoplasms of the pancreas: current guidelines do not reflect the actual risk of malignancy’, HPB (Oxford), 25(7), pp. 747-757.
  3. Solis-Pazmino, P. et al. (2024) ‘Predictors of malignant transformation in mucinous pancreatic cystic neoplasm: a systemic review and meta-analysis’, Surgical Oncology, 57, 102153.
  4. Testini, M. et al. (2010) ‘Management of mucinous cystic neoplasms of the pancreas’, World Journal of Gastroenterology, 16(45), pp. 5682-5692.
  5. National Cancer Institute (2026) Pancreatic Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.